Literature DB >> 25950278

The etiology of Rubella IgM positivity in patients with rubella-like illness in Iran from 2011 to 2013.

Seyed Mahmood Seyed Khorrami1, Talat Mokhtari-Azad1, Jila Yavarian1, Gazal Sadat Fatemi Nasab1, Maryam Naseri1, Nazanin Zahra Shafiei Jandaghi1.   

Abstract

Rubella is a mild self-limiting contagious viral disease caused by the rubella virus (RV). Although symptoms are often mild, the concern is centralized around the possible effect on a fetus growth and development in case of primary infection during early months of pregnancy. Recently acquired rubella is commonly confirmed by RV-specific IgM antibody detection in the serum. However, rubella primary infection is not always the only cause of IgM positivity. Other possible causes of rubella IgM positivity may include IgM persistence following vaccination or naturally acquired infection or even re-infection. Moreover, nonspecific IgM reactivity can cause false-positive results. There are few articles to differentiate the aetiology of rash in rubella-like illnesses. However, limited studies have been conducted on clarifying the source of IgM positivity in these cases. This article reports the study of 10,896 clinical cases demonstrating rubella-like illness between 2011 and 2013 in Iran. The rate of IgM positivity among these cases was 0.52% (57 cases). As predicted based on the high coverage of vaccination in Iran fewer than 16% of cases with ELISA IgM positive result, were due to current rubella primary infections. The greater part of the positive IgM reactions occurred in cross reactivity with other viruses (31.6%) or in prolonged IgM response post vaccination (24.6%). This research confirmed that the positive result of rubella IgM assay in vaccinated individuals is mainly caused by prolonged IgM production, rubella re-infection, and false positivity due to infection with other viruses, rather than the rubella primary infection itself.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  IgM interpretation; rubella virus; serological diagnosis

Mesh:

Substances:

Year:  2015        PMID: 25950278     DOI: 10.1002/jmv.24250

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Rubella Surveillance and Diagnostic Testing among a Low-Prevalence Population, New York City, 2012-2013.

Authors:  Beth M Isaac; Jane R Zucker; Francesca R Giancotti; Emily Abernathy; Joseph Icenogle; Jennifer L Rakeman; Jennifer B Rosen
Journal:  Clin Vaccine Immunol       Date:  2017-09-05

Review 2.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132

3.  Epidemiology of primary rubella infection in the Central African Republic: data from measles surveillance, 2007-2014.

Authors:  Alain Farra; Marilou Pagonendji; Alexandre Manikariza; Dieubéni Rawago; Rock Ouambita-Mabo; Gilbert Guifara; Ionela Gouandjika-Vasilache
Journal:  BMC Infect Dis       Date:  2016-09-23       Impact factor: 3.090

4.  The utility of measles and rubella IgM serology in an elimination setting, Ontario, Canada, 2009-2014.

Authors:  Shelly Bolotin; Gillian Lim; Vica Dang; Natasha Crowcroft; Jonathan Gubbay; Tony Mazzulli; Richard Schabas
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.